Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal

2026-01-30 08:30:11 ET

Thesis

As you probably heard, Sagimet Biosciences ( SGMT ) shares slipped about 9% yesterday. It seems their close Chinese partner, Ascletis Pharma, released some initial late-stage trial data for Denifanstat. It's a Phase 3 open-label study in which about 240 Chinese patients with moderate-to-severe acne showed that a once-daily therapy with Denifanstat was generally safe and pretty well-tolerated over 40 weeks. There were also no drug-related serious or severe adverse events, with just mostly mild-to-moderate side effects being seen. Now, despite having this positive safety profile, investors still appeared quite cautious, since overall, the update focused mainly on tolerability rather than new efficacy results. In fact, Ascletis' marketing application for Denifanstat still remains under regulatory review in China....

Read the full article on Seeking Alpha

For further details see: